Urovant Sciences (UROV) Coverage Initiated at SunTrust Banks
Stock analysts at SunTrust Banks initiated coverage on shares of Urovant Sciences (NASDAQ:UROV) in a research note issued on Friday, Marketbeat.com reports. The firm set a “buy” rating and a $24.00 price target on the stock. SunTrust Banks’ price target points to a potential upside of 70.21% from the company’s current price.
A number of other equities analysts have also commented on UROV. Zacks Investment Research upgraded shares of Urovant Sciences from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Tuesday, December 25th. HC Wainwright began coverage on shares of Urovant Sciences in a research note on Monday, March 11th. They issued a “buy” rating and a $28.00 target price on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $20.29.
Shares of UROV stock opened at $14.10 on Friday. Urovant Sciences has a 12 month low of $4.05 and a 12 month high of $14.49.
Several institutional investors have recently modified their holdings of UROV. Barclays PLC acquired a new stake in shares of Urovant Sciences in the 4th quarter valued at about $37,000. Two Sigma Investments LP acquired a new stake in shares of Urovant Sciences in the 4th quarter valued at about $72,000. Weiss Multi Strategy Advisers LLC raised its stake in shares of Urovant Sciences by 38.2% in the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock valued at $99,000 after purchasing an additional 4,146 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of Urovant Sciences in the 3rd quarter valued at about $147,000. Finally, Man Group plc acquired a new stake in shares of Urovant Sciences in the 3rd quarter valued at about $300,000. Institutional investors and hedge funds own 22.77% of the company’s stock.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Further Reading: Why does a company issue an IPO?
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.